These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 29398069)

  • 1. Ovarian cancer screening with the Risk of Ovarian Cancer Algorithm (ROCA): Good, bad, or just expensive?
    Naumann RW; Brown J
    Gynecol Oncol; 2018 Apr; 149(1):117-120. PubMed ID: 29398069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Menon U; McGuire AJ; Raikou M; Ryan A; Davies SK; Burnell M; Gentry-Maharaj A; Kalsi JK; Singh N; Amso NN; Cruickshank D; Dobbs S; Godfrey K; Herod J; Leeson S; Mould T; Murdoch J; Oram D; Scott I; Seif MW; Williamson K; Woolas R; Fallowfield L; Campbell S; Skates SJ; Parmar M; Jacobs IJ
    Br J Cancer; 2017 Aug; 117(5):619-627. PubMed ID: 28742794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Moss HA; Berchuck A; Neely ML; Myers ER; Havrilesky LJ
    JAMA Oncol; 2018 Feb; 4(2):190-195. PubMed ID: 29222541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial.
    Pinsky PF; Zhu C; Skates SJ; Black A; Partridge E; Buys SS; Berg CD
    Int J Cancer; 2013 May; 132(9):2127-33. PubMed ID: 23065684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation.
    Kearns B; Chilcott J; Whyte S; Preston L; Sadler S
    BMC Med; 2016 Dec; 14(1):200. PubMed ID: 27919292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.
    Menon U; Ryan A; Kalsi J; Gentry-Maharaj A; Dawnay A; Habib M; Apostolidou S; Singh N; Benjamin E; Burnell M; Davies S; Sharma A; Gunu R; Godfrey K; Lopes A; Oram D; Herod J; Williamson K; Seif MW; Jenkins H; Mould T; Woolas R; Murdoch JB; Dobbs S; Amso NN; Leeson S; Cruickshank D; Scott I; Fallowfield L; Widschwendter M; Reynolds K; McGuire A; Campbell S; Parmar M; Skates SJ; Jacobs I
    J Clin Oncol; 2015 Jun; 33(18):2062-71. PubMed ID: 25964255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
    Havrilesky LJ; Sanders GD; Kulasingam S; Myers ER
    Gynecol Oncol; 2008 Nov; 111(2):179-87. PubMed ID: 18722004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
    Jacobs IJ; Menon U; Ryan A; Gentry-Maharaj A; Burnell M; Kalsi JK; Amso NN; Apostolidou S; Benjamin E; Cruickshank D; Crump DN; Davies SK; Dawnay A; Dobbs S; Fletcher G; Ford J; Godfrey K; Gunu R; Habib M; Hallett R; Herod J; Jenkins H; Karpinskyj C; Leeson S; Lewis SJ; Liston WR; Lopes A; Mould T; Murdoch J; Oram D; Rabideau DJ; Reynolds K; Scott I; Seif MW; Sharma A; Singh N; Taylor J; Warburton F; Widschwendter M; Williamson K; Woolas R; Fallowfield L; McGuire AJ; Campbell S; Parmar M; Skates SJ
    Lancet; 2016 Mar; 387(10022):945-956. PubMed ID: 26707054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials.
    Skates SJ
    Int J Gynecol Cancer; 2012 May; 22 Suppl 1(Suppl 1):S24-6. PubMed ID: 22543916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should we screen for ovarian cancer? A commentary on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) randomized trial.
    Narod SA; Sopik V; Giannakeas V
    Gynecol Oncol; 2016 May; 141(2):191-194. PubMed ID: 26915499
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel risk models for early detection and screening of ovarian cancer.
    Russell MR; D'Amato A; Graham C; Crosbie EJ; Gentry-Maharaj A; Ryan A; Kalsi JK; Fourkala EO; Dive C; Walker M; Whetton AD; Menon U; Jacobs I; Graham RL
    Oncotarget; 2017 Jan; 8(1):785-797. PubMed ID: 27903971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalizing CA125 levels for ovarian cancer screening.
    Dorigo O; Berek JS
    Cancer Prev Res (Phila); 2011 Sep; 4(9):1356-9. PubMed ID: 21893498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistical approaches using longitudinal biomarkers for disease early detection: A comparison of methodologies.
    Han Y; Albert PS; Berg CD; Wentzensen N; Katki HA; Liu D
    Stat Med; 2020 Dec; 39(29):4405-4420. PubMed ID: 32939802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian cancer screening--current status, future directions.
    Menon U; Griffin M; Gentry-Maharaj A
    Gynecol Oncol; 2014 Feb; 132(2):490-5. PubMed ID: 24316306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer screening effectiveness: A realization from the UK Collaborative Trial of Ovarian Cancer Screening.
    Pavlik EJ
    Womens Health (Lond); 2016 Sep; 12(5):475-479. PubMed ID: 27595999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to the detection of ovarian cancer.
    Høgdall E
    Scand J Clin Lab Invest Suppl; 2016; 245():S49-53. PubMed ID: 27435369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening program in ovarian cancer: A logical step in clinical management? A meta-analysis.
    Marchetti C; De Felice F; Perniola G; Lecce F; Vertechy L; Monti M; Musio D; Muzii L; Tombolini V; Benedetti Panici P
    Curr Probl Cancer; 2018; 42(2):235-240. PubMed ID: 29433824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health economics of screening for gynaecological cancers.
    Kulasingam S; Havrilesky L
    Best Pract Res Clin Obstet Gynaecol; 2012 Apr; 26(2):163-73. PubMed ID: 22138003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction.
    Havrilesky LJ; Sanders GD; Kulasingam S; Chino JP; Berchuck A; Marks JR; Myers ER
    Cancer; 2011 Feb; 117(3):545-53. PubMed ID: 21254049
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.